Company news
Scholar Rock Holding Corporation news in 2022
Scholar Rock Holding Corporation's news releases, calls and decks from 2022, newest first.
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 14, 2022
Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress
November 13, 2022
Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy
November 9, 2022
Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer
November 8, 2022
New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA
October 21, 2022
Scholar Rock to Present Data from the Phase 1 DRAGON trial at the SITC 37th Annual Meeting
October 5, 2022
Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy
October 3, 2022
Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer
September 19, 2022
Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit
September 15, 2022
Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress
August 7, 2022
Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors
July 25, 2022
Scholar Rock to Participate in the 2022 Wedbush PacGrow Healthcare Conference
July 18, 2022
Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference
July 14, 2022
Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)
June 30, 2022
Scholar Rock Announces $205 Million Registered Direct Offering
June 16, 2022
Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)
June 16, 2022
Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference
June 8, 2022
Scholar Rock to Present at Jefferies Global Healthcare Conference 2022
June 1, 2022
Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities
May 15, 2022
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress
April 20, 2022
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting
March 21, 2022
Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
March 12, 2022
Scholar Rock Reports Full Year 2021 Financial Results and Highlights Business Progress
March 6, 2022
Scholar Rock to Present at Cowen’s 42nd Annual Health Care Conference
February 24, 2022
Scholar Rock to Present Biomarker Strategy for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit
January 24, 2022
Scholar Rock Provides Corporate Update and Highlights Priorities for 2022
January 9, 2022
Scholar Rock to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022
Decks in 2022
- Corporate Update (June 2022)
Corporate update · 36 slides · Jun 17, 2022
- 40th Annual J.P. Morgan Healthcare Conference 2022
Conference · 50 slides · Jan 10, 2022